PIAZZA, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.348
AS - Asia 6.276
EU - Europa 4.548
AF - Africa 1.584
SA - Sud America 1.300
OC - Oceania 136
Continente sconosciuto - Info sul continente non disponibili 65
Totale 27.257
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.528
SG - Singapore 2.369
CN - Cina 1.171
IT - Italia 1.141
BR - Brasile 801
HK - Hong Kong 684
DE - Germania 559
VN - Vietnam 399
FI - Finlandia 362
SE - Svezia 215
GB - Regno Unito 214
PL - Polonia 191
NL - Olanda 188
RU - Federazione Russa 177
IN - India 175
FR - Francia 166
UA - Ucraina 156
BJ - Benin 104
AR - Argentina 98
CI - Costa d'Avorio 96
TR - Turchia 95
CA - Canada 89
IE - Irlanda 81
JP - Giappone 77
AT - Austria 75
ID - Indonesia 75
EC - Ecuador 68
IQ - Iraq 68
ZA - Sudafrica 67
MX - Messico 60
ES - Italia 57
HN - Honduras 51
PA - Panama 51
KZ - Kazakistan 50
IL - Israele 49
AO - Angola 48
CO - Colombia 48
CV - Capo Verde 48
KE - Kenya 48
JO - Giordania 47
KG - Kirghizistan 47
PH - Filippine 47
UY - Uruguay 47
BO - Bolivia 46
CZ - Repubblica Ceca 46
EE - Estonia 46
LU - Lussemburgo 46
MY - Malesia 46
KR - Corea 45
MA - Marocco 45
SK - Slovacchia (Repubblica Slovacca) 45
TW - Taiwan 45
AM - Armenia 44
AZ - Azerbaigian 44
BA - Bosnia-Erzegovina 44
GA - Gabon 44
SA - Arabia Saudita 44
SO - Somalia 44
BB - Barbados 43
PS - Palestinian Territory 43
TT - Trinidad e Tobago 43
AE - Emirati Arabi Uniti 42
DK - Danimarca 42
DZ - Algeria 42
GR - Grecia 42
ML - Mali 42
RS - Serbia 42
UZ - Uzbekistan 42
ZW - Zimbabwe 42
BZ - Belize 41
LC - Santa Lucia 41
ME - Montenegro 41
PY - Paraguay 41
SN - Senegal 41
CG - Congo 40
CH - Svizzera 40
IR - Iran 40
PK - Pakistan 40
VE - Venezuela 40
YT - Mayotte 40
EG - Egitto 39
GN - Guinea 39
LA - Repubblica Popolare Democratica del Laos 39
MZ - Mozambico 39
NO - Norvegia 39
AL - Albania 38
BD - Bangladesh 38
BG - Bulgaria 38
CL - Cile 38
CY - Cipro 38
GT - Guatemala 38
LY - Libia 38
SI - Slovenia 38
TH - Thailandia 38
CR - Costa Rica 37
GP - Guadalupe 37
MK - Macedonia 37
NI - Nicaragua 37
NP - Nepal 37
RO - Romania 37
Totale 25.530
Salva come PNG Salva come JPEG
Città #
Fairfield 1.544
Ashburn 1.519
Singapore 1.297
Woodbridge 1.012
Ann Arbor 953
Chandler 854
Houston 776
Hong Kong 646
Cambridge 574
Seattle 574
Wilmington 506
Jacksonville 493
Beijing 357
Santa Clara 258
Boardman 250
Padova 226
Princeton 195
San Diego 177
Los Angeles 167
Munich 162
Helsinki 152
Ho Chi Minh City 127
Medford 126
New York 114
Cotonou 102
Bytom 100
Nanjing 94
Des Moines 92
Abidjan 91
Chicago 85
Guangzhou 84
Milan 83
Hanoi 76
Dublin 68
São Paulo 60
Turku 59
Pune 55
Buffalo 54
Warsaw 51
Hefei 50
Panama City 47
Amman 45
Dallas 44
Libreville 43
Baku 42
Tokyo 42
Castries 41
Dakar 41
Dong Ket 41
Nairobi 41
Bamako 40
London 40
Nuremberg 40
Vienna 40
Bishkek 39
Conakry 39
Harare 39
Orem 39
San Jose 39
Montevideo 38
Tashkent 38
Bridgetown 37
Luanda 37
Praia 37
Vientiane 35
Yerevan 35
Managua 34
Roxbury 34
Podgorica 33
Shenyang 33
Ulan Bator 33
Kigali 32
Lusaka 32
Andorra la Vella 31
Brooklyn 31
Dushanbe 31
Stockholm 31
Verona 31
Amsterdam 30
Frankfurt am Main 30
Johannesburg 30
Kampala 30
Nassau 30
Phoenix 30
San José 30
Tallinn 30
Addis Ababa 29
Montreal 29
Phnom Penh 29
Shanghai 29
Baghdad 28
Jinan 28
Lappeenranta 28
Maputo 28
Salt Lake City 28
Kinshasa 27
Niamey 27
Tirana 27
Havana 26
Istanbul 26
Totale 16.317
Salva come PNG Salva come JPEG
Nome #
R-Vemp Is a Safe and Effective Chemo-Immunotherapeutic Regimen In Elderly Unfit DLBCL Patients: Report From a Single Center-Experience 673
Major infections, secondary cancers and autoimmune diseases occur in different clinical subsets of chronic lymphocytic leukaemia patients 291
STAT3 mutation impacts biological and clinical features of T-LGL leukemia 284
Prosurvival autophagy is regulated by protein kinase CK1 alpha in multiple myeloma 277
The small GTPase RhoU lays downstream of JAK/STAT signaling and mediates cell migration in multiple myeloma 271
HSP70/HSF1 axis, regulated via a PI3K/AKT pathway, is a druggable target in chronic lymphocytic leukemia 270
3-(2,4-Dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione (SB216763), a Glycogen Synthase Kinase-3 Inhibitor, Displays Therapeutic Properties in a Mouse Model of Pulmonary Inflammation and Fibrosis 261
Protein kinase CK2 regulates AKT, NF-κB and STAT3 activation, stem cell viability and proliferation in acute myeloid leukemia 252
Protein Kinase CK2 Inhibition Down Modulates the NF-κB and STAT3 Survival Pathways, Enhances the Cellular Proteotoxic Stress and Synergistically Boosts the Cytotoxic Effect of Bortezomib on Multiple Myeloma and Mantle Cell Lymphoma Cells 239
Dominant cytotoxic NK cell subset within CLPD-NK patients identifies a more aggressive NK cell proliferation 237
Bendamustine plus rituximab is an effective first-line treatment in hairy cell leukemia variant: A report of three cases 236
Subcutaneous immunoglobulins replacement therapy in secondary antibody deficiencies: Real life evidence as compared to primary antibody deficiencies 233
Cortactin, a Lyn substrate, is a checkpoint molecule at the intersection of BCR and CXCR4 signalling pathway in chronic lymphocytic leukaemia cells. 230
Integrated CLL Scoring System, a New and Simple Index to Predict Time to Treatment and Overall Survival in Patients With Chronic Lymphocytic Leukemia 227
Epidemiology and risk factors of invasive fungal infections in a large cohort of patients with chronic lymphocytic leukemia 225
Prognostic and Predictive Effect of IGHV Mutational Status and Load in Chronic Lymphocytic Leukemia: Focus on FCR and BR Treatments 224
Actionable Strategies to Target Multiple Myeloma Plasma Cell Resistance/Resilience to Stress: Insights From “Omics” Research 216
Cross-talk between chronic lymphocytic leukemia (CLL) tumor B cells and mesenchymal stromal cells (MSCs): implications for neoplastic cell survival 214
Intrinsic and extrinsic mechanisms contribute to maintain the JAK/STAT pathway aberrantly activated in T-type large granular lymphocyte leukemia 211
BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome 210
Lights and Shade of Next-Generation Pi3k Inhibitors in Chronic Lymphocytic Leukemia 209
CX-4945, a selective inhibitor of casein kinase 2, synergizes with B cell receptor signaling inhibitors in inducing diffuse large B cell lymphoma cell death 208
Possible neuroleukemiosis in two patients with acute myeloid leukemia in complete bone marrow remission 208
Old and young actors playing novel roles in the drama of multiple myeloma bone marrow microenvironment dependent drug resistance 205
Comparative Analysis of NK Receptor and T-Cell Receptor Repertoires in Patients with Chronic Myeloid Leukemia Treated with Different Tyrosine Kinase Inhibitors 199
In Chronic Lymphocytic Leukemia the JAK2/STAT3 Pathway Is Constitutively Activated and Its Inhibition Leads to CLL Cell Death Unaffected by the Protective Bone Marrow Microenvironment 199
Aberrant expression of CD10 and BCL6 in mantle cell lymphoma 193
Protein kinase CK2 protects multiple myeloma cells from ER stress-induced apoptosis and from the cytotoxic effect of HSP90 inhibition through regulation of the unfolded protein response 193
Targeting CK2-driven non-oncogene addiction in B-cell tumors 191
Inactivation of CK1α in multiple myeloma empowers drug cytotoxicity by affecting AKT and ß-catenin survival signaling pathways 189
Multiple myeloma plasma cells show different chemokine receptor profiles at sites of disease activity 187
Analysis of Wnt and Hedgehog Pathways Regulating Protein Kinases CK1 and CK2 in Acute Myeloid Leukemia Cells and Stem Cells: Correlation with the Expression of Wnt and Hedgehog Targets and Biological and Clinical Features 187
Inhibition of protein kinase CK2 with the clinical-grade small ATP-competitive compound CX-4945 or by RNA interference unveils its role in acute myeloid leukemia cell survival, p53-dependent apoptosis and daunorubicin-induced cytotoxicity 186
Identification of the true hyperdiploid multiple myeloma subset by combining conventional karyotyping and FISH analysis 186
Idelalisib plus rituximab is effective in systemic AL amyloidosis secondary to chronic lymphocytic leukaemia 186
Ibrutinib in relapsed hairy cell leukemia variant: a case report and review of the literature 185
NK cells and CD38: Implication for (Immuno)Therapy in Plasma Cell Dyscrasias 185
Double autologous bone marrow transplantation and orthotopic liver transplantation in a patient with primary light chain (AL) amyloidosis. 183
Glycogen Synthase Kinase-3 regulates multiple myeloma cell growth and bortezomib-induced cell death 183
Peripheral neuropathies in chronic lymphocytic leukemia: a single center experience on 816 patients. 182
Dabigatran in ibrutinib-treated patients with atrial fibrillation and lymphoproliferative diseases: Experience of 4 cases 182
Cortactin expression in non-Hodgkin B-cell lymphomas: a new marker for the differential diagnosis between chronic lymphocytic leukemia and mantle cell lymphoma 182
Severe infections unrelated to neutropenia impact on overall survival in multiple myeloma patients: results of a single centre cohort study 181
B7 costimulatory molecules from malignant cells in patients with B-cell chronic lymphoproliferative disorders trigger T-cell proliferation 177
Detection of monoclonal T populations in patients with KIR-restricted chronic lymphoproliferative disorder of NK cells. 176
CD23 expression in lymphoplasmacytic lymphoma: Clinical–pathological and biological correlations 176
Splenic marginal zone lymphoma with a de novo t(8;14)(q24;q32) and a prolymphocytoid evolution responsive to rituximab-bendamustine 175
Targeting of HSP70/HSF1 Axis Abrogates In Vitro Ibrutinib-Resistance in Chronic Lymphocytic Leukemia 175
Serine-Threonine protein kinases CK1, CK2 and GSK3 in normal and malignant haematopoiesis 172
New responsibilities for aged kinases in B-lymphomas 172
Effects of CK2 inhibition on multiple signaling pathways in myeloma cells. 170
Towards a new age in the treatment of multiple myeloma 169
Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death 169
Treatment Induced Cytotoxic T-Cell Modulation in Multiple Myeloma Patients 169
Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results 168
Bone marrow stromal cell-fueled multiple myeloma growth and osteoclastogenesis are sustained by protein kinase CK2 167
CK2β-regulated signaling controls B cell differentiation and function 166
CK2 Kinase Inhibitors Display Anti-Myeloma Effects and Antagonize Osteoclast Activity in Models of Multiple Myeloma Bone Marrow Microenvironment 163
Protein kinase CK2 is widely expressed in follicular, Burkitt and diffuse large B-cell lymphomas and propels malignant B-cell growth. 161
Clinical profile associated with infections in patients with chronic lymphocytic leukemia. Protective role of immunoglobulin replacement therapy 161
Lymph node core needle biopsy in lymphoproliferative disorders - Authors' reply to Al-Abbadi and colleagues 161
Genotypic evaluation of killer immunoglobulin-like receptors in NK-type lymphoproliferative disease of granular lymphocytes 159
CD8 T cell infiltration in extravascular tissues of patients with human immunodeficiency virus infection. Interleukin-15 upmodulates costimulatory pathways involved in the antigen-presenting cells-T-cells interaction. 159
Lymph node core needle biopsy for the diagnosis of lymphoproliferative disorders: a word of caution 159
Cytogenetic Impact on Lenalidomide Treatment in Relapsed/Refractory Multiple Myeloma: A Real-Life Evaluation 158
Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell Lymphomas 158
Modulation of ER Stress/Unfolded Protein Response (UPR) Pathways in Multiple Myeloma Cells by Inhibition of Hsp90 and Serine-Threonine Kinase CK2. 158
Multiple myeloma cell survival relies on high activity of protein kinase CK2 157
Determinants of Drug Resistance in B-Cell Non-Hodgkin Lymphomas: The Case of Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia 157
Baseline prognostic predictors in classical Hodgkin Lymphoma: a retrospective, single-center analysis on patients treated with PET/CT-guided ABVD 157
Predictors of Splenectomy Response in Immune Thrombocytopenia: A Multicentric Italian Study 155
A case of “double hit” mantle cell lymphoma carrying CCND1 and MYC translocations relapsed/refractory to rituximab bendamustine cytarabine (R-BAC) and ibrutinib 155
Expression and functional role of chemokine receptors in multiple myeloma 154
Analysis of TNF-receptor and ligand superfamily molecules in patients with lymphoproliferative disease of granular lymphocytes 152
Modulation of ER Stress/Unfolded Protein Response (UPR) Pathways in Multiple Myeloma Cells by Inhibition of Hsp90 and Serine-Threonine Kinase CK2. 151
Modeling acute promyelocytic leukemia in the mouse: new insights in the pathogenesis of human leukemias. 150
Protein Kinase CK2 represents a new target to boost Ibrutinib and Venetoclax induced cytotoxicity in mantle cell lymphoma 149
A SCORING SYSTEM TO PREDICT THE RISK OF ATRIAL FIBRILLATION IN CHRONIC LYMPHOCYTIC LEUKEMIA 148
Peripheral nervous system involvement in lymphomas 147
High ETV6 Levels Support Aggressive B Lymphoma Cell Survival and Predict Poor Outcome in Diffuse Large B-Cell Lymphoma Patients 147
Dyskeratosis congenita and cancer in mice deficient in ribosomal RNA modification. 144
Signalling molecules as selective targets for therapeutic strategies in multiple myeloma 143
Protein Kinase CK1α Sustains B-Cell Receptor Signaling in Mantle Cell Lymphoma 143
Hyperforin blocks neutrophil activation of MMP-9, motility and recruitment, and restrains inflammation-triggered angiogenesis and lung fibrosis 142
Double autologous bone marrow transplantation and orthotopic liver transplantation in a patient with primary light chain (AL) amyloidosis 141
Targeting Protein Kinases in Blood Cancer: Focusing on CK1α and CK2 141
Regulation of alveolar macrophage-T cell interactions during Th1-type sarcoid inflammatory process 140
Rituximab, Bendamustine and Cytarabine (R-BAC) in patients with relapsed-refractory aggressive B-cell lymphoma 140
Role of GSK3 in multiple myeloma cell growth and survival 139
Prognostic value of heavy-chain gene mutation status and ZAP-70 expression in 113 CLL patients from a single institution 139
Continous Treatment with Ibrutinib in 100 Untreated Patients with TP53 Disrupted Chronic Lymphocytic Leukemia. A Real‐Life Campus CLL Study 138
A bone-based 3D scaffold as an in-vitro model of microenvironment–DLBCL lymphoma cell interaction 137
Role of protein kinase CK2 in the retinoic acid-induced differentiation of acute promyelocytic leukemia cells. 137
Inhibition of leukocyte elastase, polymorphonuclear chemoinvasion, and inflammation-triggered pulmonary fibrosis by a 4-alkyliden-beta-lactam with a galloyl moiety 137
Expression and functional properties of costimulatory molecules in patients with B cell chronic lymphoproliferative disorders. 137
Bortezomib-Dexamethasone As Inducion Therapy for Light Chain Deposition Disease (LCDD): A Single Center Experience 136
The risk of malignancies in celiac disease—A literature review 135
When Waldenström macroglobulinemia hits the kidney: Description of a case series and management of a “rare in rare” scenario 134
Tixagevimab/Cilgavimab as pre-exposure prophylaxis against SARS-CoV-2 in patients with hematological malignancies 133
CK1α/RUNX2 Axis in the Bone Marrow Microenvironment: A Novel Therapeutic Target in Multiple Myeloma 133
Totale 18.416
Salva come PNG Salva come JPEG
Categoria #
all - tutte 86.399
article - articoli 74.351
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 1.453
Totale 162.203
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.482 0 0 0 0 0 0 170 185 292 419 256 160
2021/20222.166 131 244 224 104 131 142 100 242 125 47 248 428
2022/20231.844 345 171 43 258 278 209 27 130 226 27 95 35
2023/20241.166 41 116 117 85 113 182 99 52 37 100 102 122
2024/20254.663 26 326 230 180 529 165 227 377 442 223 765 1.173
2025/202610.393 953 1.509 2.510 2.862 1.699 796 64 0 0 0 0 0
Totale 27.535